Table 1.
Clinico-pathological features of patients.
Figure 1.
PTK7 is able to confer oncogenic potential to NIH3T3 cells.
NIH3T3 cells were infected with PTK7wt, PTK7DN, empty vector or v-src as a positive control and then seeded for Focus Formation Assay (A) or Colony Formation Assay in Soft Agar (B).
Figure 2.
Analysis of PTK7 Expression in BC cell lines and primary tumors.
(A) Classification of BC cell lines by PTK7 expression: Cell lines Hs 578T, MDA-MB-157, BT-20, MDA-MB-468, MDA-MB-231, MDA-MB-435S, MDA-MB-436, BT-549, MCF10A1, SUM-149PT classified as basal like, MDA-MB-453, Sk-BR-3, BT-474, T-74D, ZR-75-1, MDA-MB-175VII, MDA-MB 361, BT-483, ZR-75-30, MCF7, and MDA-MB415 classified as luminal cell lines were analysed by RT-PCR. Higher PTK7 expression in BC cell lines which lack expression of ER and are grouped as basal-like. (B) Heat map of genes co-expressed with PTK7 in primary breast carcinomas (van de Vijver, Oncomine), which were grouped by ER status. The colors relate to expression units which are z-normalized to depict relative values within rows. (C) Heat map of genes co-expressed with oncogene HER3 in primary breast carcinomas (van de Vijver, Oncomine).
Figure 3.
Expression of full length PTK7 correlates with motility and invasivity of breast cancer cells.
(A) Expression of full length and dominant negative PTK7 protein in wild type or PTK7DN overexpressing Hs578T cells which were subsequently used in cellular assays. Whole cell lysates were used to detect the protein level of PTK7 by immunoblot analysis (top) with α-Tubulin as loading control (bottom). (B) Expression of PTK7 protein 48 and 72 hrs after siRNA transfection. Whole cell lysates were used to detect the protein level of PTK7 by immunoblot analysis (top) with α-Tubulin as loading control (bottom). (C) The motility of cells was analysed by Oris™ cell migration assay. Cells were allowed to migrate into the wound area for 32 hrs. Cell migration was visualized at 4× magnification, representative micrographs are shown (scale bar = 500 µm). Error bars indicate SEM (n = 3). (D) In vitro migration assay. Cells were allowed to migrate through transwell inserts for 4.5 hours. Error bars indicate SEM (n = 3). (E) The invasivity of cells was analysed by Matrigel outgrowth assay. Cells were seeded on the surface of Matrigel. Colony outgrowth was visualized at 10× magnification. (F) Matrigel Invasion Chamber Assay. Cells were allowed to invade through the Matrigel matrix and membrane pores for 20 hours. Error bars indicate SEM. (G) Effect of an anti-PTK7 polyclonal antibody on the invasivity of Hs578T cells in Matrigel outgrowth assay. Cells were seeded on the surface of Matrigel and treated with anti-PTK7 antibody or control antibody for 3 days. Colony outgrowth was visualized at 10× magnification.
Table 2.
Association of PTK7 expression and patient's clinico-pathological variables in primary tumors and lymph nodes of 128 breast cancer patients.
Figure 4.
Co-expression of Breast Cancer Related Genes and PTK7.
PTK7 and BC-related genes (Her2, Her3, Pai1, MMP1, CK19 and CD44) expression was assessed by RT-PCR and compared in LN metastasis (LNmet) and tumorfree LN (LNtfr) of 128 patients. All genes (PTK7, Her2, Her3, Pai1, MMP1, CK19) showed an overexpression in LN metastasis compared to tumorfree LN.
Table 3.
Co-expression of BC related genes and PTK7 expression in BC and LN metastases as measured by RT-PCR.
Figure 5.
PTK7 serves as a prognostic marker in lymph nodes involvement.
Kaplan-Meier curve showing disease-free survival (DFS) in breast cancer patients with lymph node metastasis classified into PTK7 low and high groups according to RT-PCR expression. PTK7 expression is associated with DFS among breast cancer patients with lymph node metastasis expressing high PTK7. P-values were calculated by the log-rank test.